STOCK TITAN

MacroGenics to Participate in Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

MacroGenics, a biopharmaceutical company focused on antibody-based cancer therapeutics, will participate in the JMP Securities Life Sciences Conference on June 16, 2022, at 12:00 pm ET. The management will engage in a fireside chat and one-on-one meetings with investors. A webcast will be available on MacroGenics' website under the Investor Relations section, with an archived replay accessible for 30 days post-event. This participation highlights MacroGenics' commitment to advancing innovative cancer treatments through strategic collaborations and proprietary technology platforms.

Positive
  • None.
Negative
  • None.

ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference in June 2022:

  • The JMP Securities Life Sciences Conference. MacroGenics’ management is scheduled to participate in a fireside chat on Thursday, June 16, 2022, at 12:00 pm ET, and will also participate in one-on-one meetings.

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain an archived replay of this webcast on its website for 30 days.

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.


FAQ

What event will MacroGenics participate in June 2022?

MacroGenics will participate in the JMP Securities Life Sciences Conference on June 16, 2022.

When is the MacroGenics fireside chat scheduled?

The fireside chat is scheduled for June 16, 2022, at 12:00 pm ET.

Where can I watch the MacroGenics investor conference presentation?

The presentation can be accessed via a webcast on MacroGenics' Investor Relations website.

Is there an archived replay of the MacroGenics presentation?

Yes, an archived replay will be available for 30 days after the event.

What is the focus of MacroGenics as a biopharmaceutical company?

MacroGenics focuses on developing innovative antibody-based therapeutics for cancer treatment.

MacroGenics, Inc.

NASDAQ:MGNX

MGNX Rankings

MGNX Latest News

MGNX Stock Data

204.36M
58.33M
2.64%
93.46%
8.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
Rockville